BAD HOMBURG, GERMANY – Newsaktuell – December 6,
2019 – Fresenius Kabi held its United for Clinical Nutrition (UCN) Satellite
Symposium during the 20th Congress of Parenteral and Enteral
Nutrition Society of Asia (PENSA) on October 9, 2019, in Hong Kong.
The symposium’s featured topic was the UCN
Nutrition Insights Day Asia (NID), a comprehensive survey led by an advisory
board and supported by Fresenius Kabi that provides insights into clinical
nutrition practices in 83 hospitals in India, Indonesia, the Philippines, South
Korea, Taiwan, Thailand and Vietnam.
Leading clinical nutrition experts were present to
discuss UCN NID: Prof. Alessandro Laviano (Italy), Prof. Rajeev Joshi (India),
Prof. Han-Hsui Hsu (Taiwan), Dr. Jesus Fernando B. Inciong (Philippines), Dr.
Winai Ungpinitpong (Thailand), and Prof. Jeong-Meen Seo (South Korea).
As nutritional deficits continue to burden the
global healthcare system, the panel of experts emphasized the importance of
prioritizing patients’ nutritional needs in order to effectively enhance
post-admission recovery. Prof. Seo said, “The time is now. No more excuses. We
must work together to bring clinical nutrition forward.”
NID results will soon be available at www.unitedforclinicalnutrition.com.
In 2014, Fresenius Kabi established UCN to raise
awareness for disease-related malnutrition around the world. Through regional
data collection and clinical assessment, and tailored events and tools for
healthcare professionals, UCN aims to reduce the prevalence of hospital
malnutrition. In 2018, the initiative expanded in Asia. To learn more, visit www.unitedforclinicalnutrition.com.
About Fresenius
Kabi
Fresenius Kabi is a global healthcare company that
specializes in lifesaving medicines and technologies for infusion, transfusion
and clinical nutrition. The company’s products and services are used to help
care for critically and�chronically ill patients. Fresenius Kabi’s product
portfolio comprises a comprehensive range of I.V. generic drugs, infusion
therapies and clinical nutrition products as well as the devices for
administering these products. In the field of biosimilars, we focus on
autoimmune diseases and oncology. In 2019, the first biosimilar product by
Fresenius Kabi was launched. Within transfusion medicine and cell technologies,
Fresenius Kabi offers products for collection and processing of blood and cell
components.
With its corporate philosophy of “caring for
life”, the company is committed to putting essential medicines and
technologies in the hands of people who help patients and finding the best
answers to the challenges they face.
For more information, please visit www.fresenius-kabi.com.
BEIJING, CHINA - Media OutReach Newswire - 8 November 2024 - Since its inception more…
Acquisition Expands TBS’ Regional Waste Management Platform in Indonesia and Singapore, aligning with its TBS2030…
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 8 November 2024 - It’s that time…
BARCELONA, SPAIN - Media OutReach Newswire - 8 November 2024 - On November 6, Central…
SINGAPORE - Media OutReach Newswire - 8 November 2024 - Singapore is strengthening its position…
PARIS, FRANCE - Media OutReach Newswire – 8 November 2024 - This year, OPPO once…